

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-jmii.com



Correspondence

Good response of low-dose steroid in a patient with COVID-19 pneumonia and autoimmune disease



Dear Editor,

We report the case of 29-year-old Taiwanese woman with coronavirus disease (COVID-19) pneumonia with fever, anosmia, ageusia, rash, and autoimmune features, who showed a good response to short-term, low-dose steroids.

The patient had lived in California, USA, where she was diagnosed with an unspecified autoimmune disorder. On the third day of home quarantine, after returning from the USA, she developed high fever, muscle soreness, and cough (day 1). Chest radiography showed bilateral infiltrates in the lung's lower lobes, and laboratory tests revealed lymphopenia (12.9%) and monocytosis (13.9%) and were negative for influenza. Nasal swab real-time polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed a cycle threshold value of 18 on day 3.

The patient experienced anosmia and ageusia on day 4-11, with high fever persistence despite the administration of empirical antibiotics, acetaminophen, ibuprofen (Fig. 1). On day 10, she developed a rash over both forearms and knees, with puffiness of her fingers (Supplemental Fig. 1). The rash was unlikely to be a drug eruption, because it disappeared briefly 7 days after stopping antibiotics and then reappeared; in total, the rash lasted 10 days. We administered a single dose of 40 mg prednisolone orally, resulting in a brief drop in temperature (Fig. 1). The high fever recurred the next day with an episode of desaturation (oxygen saturation, 93% in room air). We started oral dexamethasone 6 mg/day on days 11-14 and tapered it to 4 mg/day on days 15-16. The fever subsided, and real-time PCR from a mouth gargle and nasal swab were weakly positive for SARS-CoV-2 (Fig. 1).

Our patient's autoimmune profile was positive for antinuclear antibodies (ANA) (1:160 homogenous and speckled patterns) and anti-Ro antibodies (67 U/mL, negative <7 U/mL), equivocal for anti-cardiolipin IgG antibodies (15 G Phospholipid [GPL] U/mL, equivocal \geq 10 to \leq 40 GPL U/mL), and positive for IgM antibodies (252 M Phospholipid [MPL] U/mL, positive > 40 MPL U/mL). On days 26–32, her fever returned and we suspected Sjogren's syndrome. She

restarted oral prednisolone 10 mg/day with hydroxy-chloroquine; hydroxychloroquine was discontinued 1 day later following gastrointestinal upset. The fever subsided immediately, and the steroid was tapered and discontinued on day 36. She was discharged on day 43. She had persistently positive ANA (1:1280 homogenous, 1:1280 speckled), anti-Ro (74 U/mL), and anti-cardiolipin IgM antibodies (268 MPL U/mL) at the three-month follow-up visit.

SARS-CoV-2, the virus that has resulted in a global pandemic since 2020, can affect multiple organs and cause a cytokine storm^{1,2}; symptoms may mimic autoimmune diseases.³ February 2021, steroids have been recommended for patients with severe COVID-19 pneumonia.⁴ Low-dose steroids may reduce immunopathological damage by modulating cytokines and relieving symptoms.⁵ There are concerns, however, about steroids over-suppressing the immune response and promoting virus replications.^{5,6} More studies are needed to evaluate the safety and efficacy of a short course of low-dose steroids in patients with COVID-19 pneumonia and concomitant autoimmune diseases.

Declaration of competing interest

The authors declare no competing interests.

Funding

None required.

Ethical statement

The patient provided informed consent for publication of this manuscript.

Acknowledgement

We thank Shu-Chen Kuo, National Health Research Institutes, for his critical review.




Figure 1. The clinical response of our COVID-19 patient to steroids. Ct, cycle threshold; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronovirus 2.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jmii.2021.04.005.

References

- Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. *Brain Behav Immun* 2020;87:59—73.
- Marraha F, Al Faker I, Gallouj S. A review of the dermatological manifestations of coronavirus disease 2019 (COVID-19). Dermatol Res Pract 2020;2020:9360476.
- 3. Najafi S, Rajaei E, Moallemian R, Nokhostin F. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. *Clin Rheumatol* 2020;39:3223—35.
- Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19, version 3.4.0. 2020. https://www.idsociety.org/ practice-guideline/covid-19-guideline-treatment-and-management/#toc-5.
- Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 2020;14:1022.
- Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. *J Microbiol Immunol Infect* 2020;53:404–12.

Yea-Yuan Chang Division of Infectious Diseases, Department of Internal Medicine, Taipei City Hospital Renai Branch, Taipei, Taiwan

Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Faculty of Medicine, School of Medicine, Taipei, Taiwan Institute of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan

Wen-Hsiu Wang

Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei City, Taiwan

Department of Medicine, Mackay Medical College, Taipei City, Taiwan

> Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan

> > Stephane Wen-Wei Ku*

Division of Infectious Diseases, Department of Internal Medicine, Taipei City Hospital Renai Branch, Taipei, Taiwan

Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

*Corresponding author. Division of Infectious Diseases, Department of Internal Medicine, Taipei City Hospital Renai Branch, Taipei, Taiwan. Fax: +886 2 2703 5325. E-mail address: stephaneku@gmail.com (S.W.-W. Ku)

> 27 November 2020 Available online 12 May 2021